These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 8875213

  • 1. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
    Nieborowska-Skórska M, Białek AP, Nicolaides NC, Iozzo RV, Kawalec M, Calabretta B, Kawiak J, Marlicz K, Skórski T.
    Folia Histochem Cytobiol; 1996; 34(2):69-73. PubMed ID: 8875213
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.
    Blood; 1996 Aug 01; 88(3):1005-12. PubMed ID: 8704208
    [Abstract] [Full Text] [Related]

  • 4. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B.
    Proc Natl Acad Sci U S A; 1994 May 10; 91(10):4504-8. PubMed ID: 8183938
    [Abstract] [Full Text] [Related]

  • 5. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B.
    Leukemia; 1997 Jun 10; 11(6):811-9. PubMed ID: 9177433
    [Abstract] [Full Text] [Related]

  • 6. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 10; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

  • 7. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ.
    Leukemia; 1995 Jan 10; 9(1):118-30. PubMed ID: 7845006
    [Abstract] [Full Text] [Related]

  • 8. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM.
    Leuk Lymphoma; 1993 Jan 10; 11 Suppl 1():131-7. PubMed ID: 7504543
    [Abstract] [Full Text] [Related]

  • 9. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Jan 10; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 10. A model of Ph' positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice.
    Skórski T, Nieborowska-Skórska M, Calabretta B.
    Folia Histochem Cytobiol; 1992 Jan 10; 30(3):91-6. PubMed ID: 1286728
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.
    J Clin Invest; 2007 Sep 10; 117(9):2408-21. PubMed ID: 17717597
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA.
    Anticancer Drug Des; 1997 Jul 10; 12(5):383-93. PubMed ID: 9236854
    [No Abstract] [Full Text] [Related]

  • 15. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 10; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 16. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P, Amadori S, Calabretta B, Mandelli F.
    Bone Marrow Transplant; 1993 Sep 10; 12(3):261-5. PubMed ID: 8241986
    [Abstract] [Full Text] [Related]

  • 17. [Adverse effects of parenteral administration of antisense oligonucleotides].
    Białek A, Kawalec M, Hoser G, Kawiak J, Krygier-Stojałowska A, Skórski T, Marlicz K.
    Pol Arch Med Wewn; 2001 May 10; 105(5):361-7. PubMed ID: 11865587
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C, Calabretta B.
    Cancer Res; 1996 Oct 01; 56(19):4332-7. PubMed ID: 8813118
    [Abstract] [Full Text] [Related]

  • 19. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
    Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B.
    J Exp Med; 1995 Dec 01; 182(6):1645-53. PubMed ID: 7500009
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.